cbdMDYCBD +0.75%38 Buyback Yield % is 0.00 as of Jul. 04, 2026. GuruFocus rates YCBD with a GF Score™ of 38/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 292 Drug Manufacturers companies, cbdMD ranks worse than 342465.41% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for cbdMD's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YCBD vs AKAN, GELS, SNOA: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, cbdMD's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
cbdMD Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, cbdMD's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where cbdMD's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
cbdMD (YCBD) has a Buyback Yield % of 0.00 as of Jul. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on cbdMD and its competitors. According to the industry distribution chart, cbdMD ranks #999999 out of 292 companies in the Drug Manufacturers industry.
Is cbdMD's Buyback Yield % too high?
cbdMD's current Buyback Yield % is 0.00. Based on the distribution chart, cbdMD ranks #999999 out of 292 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, cbdMD has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does cbdMD's Buyback Yield % compare to AKAN and GELS?
According to the Drug Manufacturers industry distribution chart, cbdMD ranks #999999 out of 292 companies for Buyback Yield %. This places cbdMD in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on cbdMD and its competitors. cbdMD's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is cbdMD stock overvalued right now?
Based on GuruFocus' analysis, cbdMD (YCBD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $0.69 — trading 328.1% above its estimated fair value. The current Buyback Yield % is 0.00. cbdMD's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For cbdMD (YCBD), the current Buyback Yield % is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is cbdMD (YCBD) Overvalued in 2026?
Based on GuruFocus' analysis, cbdMD stock appears to be overvalued.
The current stock price of $0.69 is trading 328.1% above its estimated GF Value™ of $0.16.
GuruFocus considers cbdMD to be Significantly Overvalued.
Key valuation signals for YCBD:
Buyback Yield %: 0.00
GF Value™: $0.16 vs. price of $0.69 (328.1% above fair value)
No single metric tells the full story. See the YCBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
38GF Score
Get the complete analysis for YCBD
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YCBD has been successfully added to your 
